European Commission clears J&J's ustekinumab

01/22/2009 | Bloomberg

Johnson & Johnson announced that the European Commission approved the use of ustekinumab, a psoriasis treatment, for patients who do not benefit from other anti-inflammatory medicines. In December, the FDA deferred its decision on the drug and asked J&J to submit additional safety data.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA